- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02361099
SENTINEL : Impact of the Use of a Web-application for the Detection of Lung Cancer Relapse (SENTINEL)
Phase 3 Multicentric Randomized Study Assessing Self-reported Symptoms Transmitted Via an Internet Web-application " Sentinel " Versus Conventional Follow-up in Patients With High Risk Lung Cancer (SENTINEL)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
With a 5-year survival of about 15% pulmonary cancer is very poor prognosis. About 70 to 75% of cancers are diagnosed at advanced stages. Relapses are common and rarely curable. At least 75% of relapses are symptomatic and there is no standard monitoring after curative treatment or not. Currently, the most common monitoring strategy involves the completion of a clinical examination every 3 to 6 months associated with chest X-ray or CT-scan.
An intensive clinical and imaging monitoring has not yet shown any survival advantage but monitoring of symptoms appears to have a significant medical and economic advantage compared to imaging monitoring. This non-personalized approach is a source of anxiety for patients, especially with the approach of the date of the imaging assessment. In contrast, this monitoring can leave symptomatic patients with untreated relapse for several weeks because many symptomatic patients wait the date of the imaging assessment to consult.
the investigators have developed a score based on the dynamics and the association of clinical signs to alert the physician to a possible recurrence of lung cancer. The referring physician is alerted so early and convenes the patient for a checkup. One of the explanations which could demonstrate the gain in survival is the possibility offered by the application SENTINEL is to treat the relapses earlier, thus avoiding to wait a too much important deterioration of general condition between two monitoring follow-up more or less spaced.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Angers, France, 49933
- Centre Hospitalier Universitaire
-
Angers, France, 49933
- Institut de cancérologie de l'Ouest - Site Paul Papin
-
Avignon, France, 84918
- Institut Sainte Catherine
-
Chartres, France, 28018
- Centre Hospitalier General
-
La Roche Sur Yon, France, 85925
- Centre Hospitalier Départemenal
-
Le Mans, France, 72000
- Centre Jean Bernard
-
Le Mans, France, 72037
- Centre Hospitalier
-
Nantes, France, 44202
- Centre Catherine de Sienne
-
Saint Herblain, France, 44805
- Institut de Cancérologie de l'Ouest - Site René Gauducheau
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient with lung cancer (NSCLC and SCLC), histologically proven
- Patient at high risk of relapse (TxN1, IIIA, IIIB, IV stages)
- Age ≥ 18 ans
- PS ≤ 2 within 15 days before enrollment
Patient having:
finished his cancer treatment in the last 3 months by:
- Surgery or
- Surgery then adjuvant chemotherapy or
- Concomitant radio-chemotherapy or
- Conventional or stereotactic radiotherapy or
- 1st or 2nd line chemotherapy
- treatment with TKI (tyrosine kinase inhibitor) in 1st or 2nd line or maintenance treatment with Alimta® and / or Avastin® or Gemzar® well tolerated (SENTINEL 's score with this treatment (TKI or maintenance) to its latest assessment.
- Patient with an initial SENTINEL score ≤ 6
- Patient with internet access and an e-mail box
- Patient affiliated to a social security scheme
- Patient has given its written consent before any specific procedure from protocol
Exclusion Criteria:
- Patient whose disease has progressed at the end of the specific treatment
- Symptomatic brain metastases
- Persons deprived of liberty or under guardianship or curators
- Dementia, mental alteration or psychiatric pathology that can compromise informed consent from the patient and / or adherence to the protocol and the monitoring of the trial
- Patient who cannot submit himself to the followed of the protocol for psychological reasons, social, family or geographical
- Pregnant or breastfeeding women
- Patient participating in another interventional study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Monitoring by SENTINEL application
Patients randomized to this arm will connect once a week to SENTINEL application to do a self-evaluation of several symptoms.
A CT- scan will be scheduled only when there is an alert of the application.
|
Patients will connect once a week to SENTINEL application to do a self-evaluation of several symptoms.
A CT- scan will be scheduled only when there is an alert of the application
Other Names:
|
No Intervention: Conventional Monitoring
Patients randomized to this arm will have a CT-scan every 3 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: 24 months
|
Overall survival is defined as the period between the date of randomization to the date of death from any cause.
We will also evaluate in this context the overall survival defined between the date of diagnosis and date of death whatever the cause in order to know more precisely the duration of the disease.
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of Life (QOL)
Time Frame: 12 month
|
The quality of life will be studied using the questionnaire FACT-L at baseline and follow-up visits at 3, 6 and 12 months.
|
12 month
|
Depression
Time Frame: 12 month
|
Patient's depression will be assessed through the questionnaire HUMEUR PHQ9 at baseline and follow-ups at 3, 6 and 12 months.
|
12 month
|
Relapse detection time
Time Frame: 24 month
|
The relapse detection time is defined as time from the date of diagnosis to the date of highlighting of the recurrence by imaging
|
24 month
|
Performance Status (PS)
Time Frame: 24 month
|
Performance Status will be evaluated according to WHO recommendations.
|
24 month
|
Cost of monitoring
Time Frame: 24 month
|
The cost of monitoring will be evaluated from the perspective of health insurance.
|
24 month
|
Patient compliance
Time Frame: 24 month
|
Patient compliance to the use of SENTINEL application will be evaluated according to the number of assessments completed (usually 1 per week) compared to the theoretical maximum number filling weekly and monthly the application over time.
|
24 month
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Fabrice DENIS, MD, Centre Jean Bernard - LE MANS
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WP-2018-01
- 2014-A00263-44 (Other Identifier: RCB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
Dana-Farber Cancer InstituteMedWaves, IncNot yet recruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Head and Neck Carcinoma | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditionsUnited States
Clinical Trials on Monitoring by SENTINEL application
-
Institut Cancerologie de l'OuestTerminated
-
Hospital DonostiaRecruitingDiagnostic Value of Sentinel Node Biopsy Guided by Magnetic ProbeSpain
-
Mayo ClinicCompleted
-
Brainmarc Ltd.Unknown
-
NSABP Foundation IncNational Cancer Institute (NCI)CompletedBreast CancerCanada, United States, Puerto Rico
-
Ain Shams UniversityNot yet recruiting
-
Deutsches Herzzentrum MuenchenCompletedImprovement of Treatment SatisfactionGermany
-
National University Hospital, SingaporeCompletedPeriodontitis | Gingivitis | Plaque, DentalSingapore
-
Betul Zeynep YildizEnrolling by invitation
-
Poitiers University HospitalCompletedMajor Surgery in Adult PatientsFrance